Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36,715 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo comparator Clear all
Active, not recruiting Phase 2Phase 3 Interventional

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

NCT03743649
View directory record Official record
Conditions
Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Haloperidol, Lorazepam, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Use of N-Acetylcysteine (NAC) in Fingernail Biting

NCT01993849
View directory record Official record
Conditions
Onychophagia
Interventions
N-Acetylcysteine (NAC), Placebo
Drug · Other
Lead sponsor
Kevin Gray, MD
Other
Eligibility
18 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 2, 2026, 10:02 AM EDT
Terminated Not applicable Interventional

Assessing Neurocognitive Effects of Gluten Exposure

NCT01506349
View directory record Official record
Conditions
Celiac Disease, Neurobehavioral Manifestations
Interventions
gluten, Placebo
Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

ACTIVE: Advanced Cognitive Training for Independent and Vital Elderly

NCT00298558
View directory record Official record
Conditions
Aging, Healthy
Interventions
Cognitive Training
Behavioral
Lead sponsor
Carelon Research
Other
Eligibility
65 Years and older
Enrollment
2,832 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Not applicable Interventional

The Utility of Virtual Reality in the Management of Pediatric Functional Constipation With Pelvic Floor Dysfunction.

NCT04172948
View directory record Official record
Conditions
Functional Constipation, Pelvic Floor Disorders
Interventions
Oculus go headset/virtual reality headset, Diaphragmatic breathing
Device · Behavioral
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Sep 2, 2026, 10:02 AM EDT
Terminated Phase 3 Interventional

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

NCT00396448
View directory record Official record
Conditions
Obesity
Interventions
CP-945,598 Treatment B, CP-945,598 Treatment A, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Peoria, Arizona • Newport Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Not applicable Interventional

Local Anesthetic Infiltration and Infusion for Pain Control After Hip Replacement

NCT01409278
View directory record Official record
Conditions
Osteoarthritis
Interventions
Ropivacaine infiltration and saline infusion., Ropivacaine infiltration and infusion., Normal Saline
Procedure
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years to 80 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

NCT00791778
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Sorafenib (Nexavar, BAY43-9006), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
La Jolla, California • Jacksonville, Florida • Augusta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 2, 2026, 10:02 AM EDT
Terminated Phase 3 Interventional Results available

Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis

NCT04984278
View directory record Official record
Conditions
Spasticity With Multiple Sclerosis
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Denver, Colorado • Naples, Florida • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 2, 2026, 10:02 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT06252285
View directory record Official record
Conditions
RSV Immunisation
Interventions
RSVt Vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 21 Months
Enrollment
6,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
50
States / cities
Birmingham, Alabama • Guntersville, Alabama • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

Repinotan in Patients With Acute Ischemic Stroke

NCT00044915
View directory record Official record
Conditions
Stroke, Acute Ischemic Stroke
Interventions
Repinotan HCl (BAYX3702), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
28
States / cities
Los Angeles, California • Oceanside, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2009 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously

NCT00333515
View directory record Official record
Conditions
Healthy Volunteers, Chemical Terrorism, Chemical Warfare
Interventions
Human Butyrylcholinesterase (HuBChE) derived from human plasma, Placebo: Normal saline
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 3 Interventional

American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm

NCT00259376
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
Dronedarone (SR33589), placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
21 Years and older
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 14, 2010 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

NCT03281876
View directory record Official record
Conditions
Respiratory Disorders
Interventions
NTHi Mcat investigational vaccine (GSK3277511A), Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Mesa, Arizona • Phoenix, Arizona • Palm Springs, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

NCT02942017
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Results available

Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome

NCT01452789
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
sublingual buprenorphine, oral morphine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 2Phase 3 Interventional

Efficacy Study of Subcutaneous Methyl-B12 in Children With Autism

NCT00273650
View directory record Official record
Conditions
Autistic Disorder
Interventions
methylcobalamin, saline placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 8 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 2 Interventional

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

NCT06862791
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD9550, AZD6234, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
29
States / cities
Dothan, Alabama • Vestavia Hills, Alabama • Cerritos, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Long-Term Safety Study of Tafenoquine

NCT03320174
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tafenoquine, Placebo
Drug · Other
Lead sponsor
60 Degrees Pharmaceuticals LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Colorado Springs, Colorado • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement

NCT00729690
View directory record Official record
Conditions
PAIN
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
Asokumar Buvanendran
Other
Eligibility
55 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 18, 2012 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Constipation Fiber Trial

NCT02193997
View directory record Official record
Conditions
Functional Constipation in Children
Interventions
Fiber, Placebo
Other
Lead sponsor
Warren Bishop
Other
Eligibility
2 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Phase 2 Interventional Results available

Caplyta in Borderline Personality Disorder

NCT05356013
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Caplyta, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 2, 2026, 10:02 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Assess SLN124 in Patients With Polycythemia Vera

NCT05499013
View directory record Official record
Conditions
Polycythemia Vera
Interventions
SLN124, Placebo
Drug
Lead sponsor
Silence Therapeutics plc
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
5
States / cities
Hammond, Louisiana • Buffalo, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 2, 2026, 10:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Seeing the World Through Assorted Glasses

NCT02483559
View directory record Official record
Conditions
Sleep
Interventions
Amber Lenses, Placebo Lenses
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 2, 2026, 10:02 AM EDT